What is the current stock price of BioRestorative Therapies, Inc. (BRTX)?

As of the latest market data, BioRestorative Therapies, Inc. (BRTX) is trading at $0.24. The stock has seen a gain of 0.25% today.

Does BioRestorative Therapies, Inc. (BRTX) pay a dividend?

Based on current data, BioRestorative Therapies, Inc. does not have a confirmed active dividend policy.

What is the market cap of BioRestorative Therapies, Inc.?

The current market capitalization of BioRestorative Therapies, Inc. (BRTX) is approximately unavailable.

BRTX

BioRestorative Therapies, Inc.·Healthcare

0.24

0.250%(+0.00)

Market Closed

0.28

15.919%(+0.04)

After Hours

Last Updated: — ET

52W L: $0.1952W H: $2.04

BRTX NEWS

globenewswire.com

4d ago

BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

Partnership to drive brand architecture, go-to-market execution, and global launch of the Company's product portfolio bridging biotechnology and premium skincare

globenewswire.com

Mar 30

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal stem cells Presented at the 2026 Orthopaedic Research Society Annual Meeting MELVILLE, N.Y., March 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced blinded data from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc disease, with 50% or more of treated patients reporting improvements >50% across key pain and functional outcome measures and no adverse events related to dose-limiting toxicities.

zacks.com

Mar 26

Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates

Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.2 per share a year ago.

globenewswire.com

Mar 19

BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company's proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 Orthopaedic Research Society Annual Meeting

globenewswire.com

Mar 5

BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026

Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy

defenseworld.net

Mar 3

BioRestorative Therapies (OTCMKTS:BRTX) Share Price Passes Below Fifty Day Moving Average – Here’s Why

BioRestorative Therapies, Inc. (OTCMKTS:BRTX - Get Free Report) crossed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $0.88 and traded as low as $0.20. BioRestorative Therapies shares last traded at $0.2138, with a volume of 2,454,036 shares. BioRestorative Therapies Stock Down 6.4% The firm has

Company Profile

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2012-12-05

Beta

0.27

Websitewww.biorestorative.com↗